User:Mr. Ibrahem/Mogamulizumab

Mogamulizumab, sold under the brand name Poteligeo, is a medication used to treat mycosis fungoides and Sézary disease. It is used when other treatments are not effective. It is given by gradual injection into a vein.

Common side effects include rash, pneumonia, fever, and cellulitis. Other side effects may include Stevens-Johnson syndrome, sepsis, pneumonitis, myocarditis, and polymyositis. Use in pregnancy may harm the baby. It is a monoclonal antibody that binds to CC chemokine receptor 4 (CCR4) found on white blood cells.

Mogamulizumab was approved for medical use in the United States and Europe in 2018. In the United Kingdom 4 mg cost the NHS about £1,300 as of 2021. This amount in the United States costs about 4,200 USD.